Risk Analysis: CURE IT COMPOSITES LIMITED

1. Risk Rating: MEDIUM

The company demonstrates solid solvency with net assets of £8.4M and positive profitability, but exhibits concerning trends including a significant decline in net profit (approximately 59% year-on-year), steadily eroding cash reserves, and declining revenues. The acknowledged market uncertainty and raw material cost pressures elevate the risk profile from low, though the long-established trading history (40+ years) and substantial equity base provide meaningful downside protection.

2. Key Concerns

a) Profitability Deterioration Net profit before tax fell from £3,242,503 (FY2024) to £1,337,812 (FY2025) — a decline of approximately 59%. The directors attribute this partially to an "exceptional item reported in note 6," though the full details are truncated in the filed accounts. Additionally, direct costs as a percentage of sales increased from 67.7% to 70.0%, compressing gross margins from 32.3% to 31.0%. This margin erosion, combined with the exceptional charge, warrants scrutiny.

b) Declining Cash Position Cash has fallen from £4.07M (FY2021) to £1.65M (FY2025) — a reduction of approximately 60% over four years. While total liabilities have decreased year-on-year (from £3.84M to £2.53M), the sustained cash depletion raises questions about whether capital expenditure, dividend distributions, or operational cash burn is driving this trend. The current cash represents approximately 7% of annual turnover, which may limit financial flexibility.

c) Revenue Contraction and Market Uncertainty Turnover declined from £25.4M to £24.1M (approximately -5.3%). The directors explicitly note that market conditions have impacted the construction industry, with lower spend per account and per order. The outlook is described as "uncertain," and while the company reports market share expansion, this has not offset the volume decline.

3. Positive Indicators

Strong Equity Base: Net assets of £8.4M against total liabilities of £2.53M provides a healthy liability-to-equity ratio of approximately 0.30:1, indicating substantial buffer for creditors.

Reduced Total Liabilities: Total liabilities decreased from £3.84M (FY2024) to £2.53M (FY2025), suggesting active deleveraging or repayment of obligations, which strengthens the balance sheet.

Long-Established Trading History: Incorporated in 1984, the company has operated for over 40 years, demonstrating resilience through multiple economic cycles. The recent rebrand from G. & B. (North West) Limited to Cure It Composites Limited (September 2024) signals strategic investment in brand identity.

Product Innovation: The February 2025 launch of "Cure It One" — a simplified one-coat GRP system — represents ongoing investment in product development and a potential differentiator in a competitive market.

Regulatory Compliance: Accounts and confirmation statements are filed on time with no overdue filings. The company is audited (McDade Roberts Accountants Limited), providing additional assurance on financial reporting.

4. Due Diligence Notes

Exceptional Item (Note 6): The strategic report references an exceptional item that significantly impacted net profit. The truncated accounts text prevents full analysis. This must be obtained and reviewed to determine whether it is non-recurring or indicative of an underlying structural issue.

Cash Flow Dynamics: The sustained decline in cash from £4.07M to £1.65M over four years requires explanation. Specifically, determine the breakdown between capital expenditure, dividend distributions, working capital movements, and operational cash generation. The FY2022 cash position of only £569,824 (before recovering to £2.85M in FY2023) suggests potential volatility.

FY2021 to FY2022 Net Asset Decline: Net assets fell from £11.18M (FY2021) to £6.06M (FY2022) — a drop of approximately £5.1M. This warrants investigation to understand whether this reflects asset write-downs, dividend stripping, trading losses, or revaluation adjustments.

Related Party Transactions: Giants Hall Holdings Limited holds over 75% of shares and voting rights. Inter-company transactions, management charges, or dividend policies between the subsidiary and parent should be examined for potential cash extraction or transfer pricing concerns.

Glass Fibre Price Exposure: The directors highlight volatility in glass fibre prices as a material cost pressure. Understanding the company's hedging strategy, supplier concentration, and ability to pass through cost increases to customers is essential for assessing margin sustainability.

Capital Expenditure and Production Capacity: The strategic report mentions investment in "production capacity" alongside the Cure It One launch. Clarifying the scale and phasing of this investment, and whether it is debt-funded or from cash flow, would inform liquidity projections.